XBiotech Announces Additions To Its Scientific Advisory Board
(Thomson Reuters ONE) -
AUSTIN, Texas, April 10, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) is
pleased to announce the appointments of four leading physicians to its
Scientific Advisory Board (SAB) specializing in Oncology: Dr. Thierry André,
Head of Medical Oncology Department, St. Antoine Hospital, Assistance Publique
Hôpitaux de Paris; Dr. George Fisher of Stanford University; Dr. Andrew
Hendifar, Co-Director of Cedars-Sinai; Dr. Alexander Knuth, Professor Emeritus
University of Zurich; and Dr. Razelle Kurzrock, Chief of Hematology & Oncology,
UC San Diego School of Medicine.
Dr. Alexander Knuth commented, "I have been delighted to follow XBiotech's
remarkable portfolio and growth over the years. XBiotech has developed an
entirely new class of cancer therapeutics. Targeting inflammatory pathways in
cancer patients with truly human derived monoclonal antibodies is proven to
stabilize disease and improve performance and quality of life, even in heavily
pretreated patients with advanced disease. As an oncologist, I recognize the
urgent need for effective therapies without the toxicities encountered with most
established cancer therapeutics. I am honored to formally serve as an advisor
with my esteemed colleagues to help bring this important new treatment modality
to cancer patients in need."
XBiotech's SAB Members in Oncology Include:
* Thierry André, M.D. Dr. André is currently Professor of Medical Oncology at
the University Pierre et Marie Curie (UMPC), Paris VI, and Head of the
Medical Oncology Department in St. Antoine Hospital, Assistance Publique
Hôpitaux de Paris. He is the Founding member and General Secretary of the
GERCOR (Multidisciplinary Oncology Research Group) and leads the colorectal
task force of GERCOR and also serves as a Member of the Adjuvant Colon
Cancer Endpoints (ACCENT) group. Dr. André's main research interest is in
gastrointestinal malignancies. Dr. André is a member of several scientific
organizations including the American Society of Clinical Oncology (ASCO) and
the European Society for Medical Oncology (ESMO), and was chairman of the GI
Cancer Board for Research of the French National Institute (INCA).
* George A. Fisher, Jr. M.D., Ph.D. Dr. Fisher is a medical oncologist and
gastrointestinal specialist and is the Colleen Haas Chair at Stanford
University School of Medicine. Dr. Fisher has been the National Chair of
XBiotech's Phase III study since evaluating the Company's lead antibody
product candidate for the treatment of advanced colorectal cancer. His
clinical and research interests are focused on gastrointestinal
malignancies, combined modality therapy in gastric, esophageal, pancreas and
rectal cancers, immunotherapy, and translational research. He is a member of
the Stanford Cancer Institute and has held numerous administrative
appointments at the Stanford University School of Medicine including
Director for the Cancer Clinical Trials Office.
* Andrew Hendifar, M.D. Dr. Hendifar is the Co-Director of Pancreas Oncology
and Medical Oncology Lead for Gastrointestinal Disease Research at Cedars-
Sinai. Dr. Hendifar has been an important Principal Investigator in
XBiotech's Phase III study for colorectal cancer, where he has made
important clinical observations in patients. Dr. Hendifar is performing
pioneering work in the development of new approaches to treat and evaluate
therapies in pancreatic cancer. His work to elucidate the importance of body
mass index and biomarkers as prognosticators in cancer is providing new
insight on the importance of new measures in disease management and
therapeutic strategies. Dr. Hendifar's findings have been published in
prestigious journals, including the Lancet, Cancer, Journal of Clinical
Oncology, and Clinical Cancer Research. Dr. Hendifar has displayed deep
subject-matter knowledge in presentations for organizations such as the
National Institutes of Health and the American Society of Clinical
Oncology.
* Alexander Knuth, M.D. Dr. Knuth is a medical oncologist with a long research
interest and major contributions to cancer immunology. For years, Dr. Knuth
worked closely with Dr. Lloyd Old and the Ludwig Institute for Cancer
Research, pioneering the characterization of tumor associated antigens and
immunotherapies. Dr. Knuth is Professor Emeritus of the University of Zurich
where he held the Chair of Internal Medicine/Oncology at the University
Hospital (UZH) from 2003 until 2013. At UZH, Dr. Knuth used XBiotech's
candidate therapeutic antibody for colorectal cancer under compassionate
protocols. Prior to heading oncology at UZH, Dr. Knuth was Chief Physician
of Hematology & Oncology at Northwest Hospital in Frankfurt, Germany. He has
received many awards, including the prestigious Johann-Georg-Zimmermann
Medal. Dr. Knuth is a member of the Cancer Research Institute's (CRI)
Scientific Advisory Council and is a member of CRI's global clinical
investigator network. Dr. Knuth is currently the Medical Director and Chief
Executive Officer of the National Center for Cancer Care and Research
(NCCCR) and Chairman of Cancer Services at Hamad Medical Corporation in
Doha, Qatar.
* Razelle Kurzrock, M.D. Dr. Kurzrock is a medical oncologist and a renowned
expert in precision medicine. She is a thought leader in the use of anti-
cytokine therapies for the treatment of cancer and one of the first to
recognize the importance of the interleukin-1 pathway in cancer. While at
the University of Texas MD Anderson Cancer Center, Dr. Kurzrock built one of
the most successful Phase 1 clinical trials programs in the nation, and was
the senior author in the pioneering study for the Company's colorectal
cancer study. Dr. Kurzrock currently serves as Senior Deputy Center Director
for Clinical Science, Director at the Center for Personalized Cancer
Therapy, Director of the Clinical Trials Office, and a Team Leader for
Experimental Therapeutics at the Moores Cancer Center at UC San Diego. Dr.
Kurzrock is also Chief of the Hematology & Oncology Division in the UC San
Diego School of Medicine.
John Simard, President & CEO of XBiotech, commented, "It is more than gratifying
to have these remarkable people share their knowledge and experience with us. We
are indeed brought together by the common will to advance new therapies for
cancer."
About True Human(TM) Therapeutic Antibodies
XBiotech's True Human(TM) antibodies are derived without modification from
individuals who possess natural immunity to certain diseases. With discovery and
clinical programs across multiple disease areas, XBiotech's True Human
antibodies have the potential to harness the body's natural immunity to fight
disease with increased safety, efficacy and tolerability.
About XBiotech
XBiotech is a fully integrated global biosciences company dedicated to
pioneering the discovery, development and commercialization of therapeutic
antibodies based on its True Human(TM) proprietary technology. XBiotech
currently is advancing a robust pipeline of antibody therapies to redefine the
standards of care in oncology, inflammatory conditions and infectious diseases.
Headquartered in Austin, Texas, XBiotech also is leading the development of
innovative biotech manufacturing technologies designed to more rapidly, cost-
effectively and flexibly produce new therapies urgently needed by patients
worldwide. For more information, visit www.xbiotech.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations
regarding management's beliefs and expectations that involve substantial risks
and uncertainties. In some cases, you can identify forward-looking statements by
terminology such as "may," "will," "should," "would," "could," "expects,"
"plans," "contemplate," "anticipates," "believes," "estimates," "predicts,"
"projects," "intend" or "continue" or the negative of such terms or other
comparable terminology, although not all forward-looking statements contain
these identifying words. Forward-looking statements are subject to inherent
risks and uncertainties in predicting future results and conditions that could
cause the actual results to differ materially from those projected in these
forward-looking statements. These risks and uncertainties are subject to the
disclosures set forth in the "Risk Factors" section of certain of our SEC
filings. Forward-looking statements are not guarantees of future performance,
and our actual results of operations, financial condition and liquidity, and the
development of the industry in which we operate, may differ materially from the
forward-looking statements contained in this press release. Any forward-looking
statements that we make in this press release speak only as of the date of this
press release. We assume no obligation to update our forward-looking statements
whether as a result of new information, future events or otherwise, after the
date of this press release.
Contact
Ashley Otero
aotero(at)xbiotech.com
512-386-2930
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: XBiotech, Inc via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 10.04.2017 - 16:41 Uhr
Sprache: Deutsch
News-ID 535531
Anzahl Zeichen: 10738
contact information:
Town:
Austin
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 309 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"XBiotech Announces Additions To Its Scientific Advisory Board"
steht unter der journalistisch-redaktionellen Verantwortung von
XBiotech, Inc (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
